* ALL = acute lymphocytic leukemia; AP = accelerated phase; BC = blast crisis; CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; CRC = colorectal cancer; EGFR = epidermal growth factor receptor; FU/LV = fluorouracil and leucovorin; GIST = gastrointestinal stromal tumor; HR = hormone receptor; LHRH = luteinizing hormone-releasing hormone; NSCLC = non-small cell lung cancer; Ph = Philadelphia chromosome. † At conversion, product had an indication that differed from the initial one at accelerated approval.
Regulatory History
Oncology products include both drug products and biological products. Accelerated approval of drug products is authorized under Subpart H of the New Drug Regulations (1) and accelerated approval of biological products is authorized under Subpart E of the Biological Licensing Regulations (2). For simplicity, in this review the term "drugs" is used to refer to both drug products and biological products.
Marketing approval of drugs in the United States requires substantial evidence of clinical benefit (or efficacy) from adequate and well-controlled investigations (3). Efficacy should be demonstrated by the prolongation of life, improvement in the quality of life through the prevention or amelioration of cancer-related symptoms, or an established surrogate for either of these endpoints. In this article, we will refer to this type of approval as "regular approval."
In 1992, new regulations were published (1,2) that allowed for accelerated approval of drugs that appeared to provide benefit over available therapy for serious or life-threatening diseases. Accelerated approval is based on a surrogate endpoint that is reasonably likely to predict clinical benefit, such as a prolongation of life or a better quality of life. Following accelerated approval, pharmaceutical companies are required to conduct postapproval clinical trials to confirm that the drug provides clinical benefit, as predicted by the surrogate endpoint. If a company does not confirm clinical benefit by conducting a postapproval clinical trial(s) with due diligence, the regulations allow the drug to be removed from the market (1,2).
For some indications for which a drug demonstrates clinical benefit, accelerated approval is granted instead of regular approval because of uncertainty about the ultimate outcome of patients who are treated with the drug (1,2). For example, for the adjuvant breast cancer indication, improved disease-free survival is considered an established surrogate for improved survival or a better quality of life; however, longer follow-up is needed to obtain essential information for patients and physicians regarding long-term survival and toxicity. Another example is in chronic myelogenous leukemia in chronic phase: A delay in progression to accelerated phase or blast crisis is an established surrogate for clinical benefit; however, because this is a chronic disease with a long survival, the ultimate outcome is survival duration.
For regular approval of a drug, clinical benefit must be demonstrated. Several clinical trial endpoints are used for demonstrating clinical benefit (4-6). Although improvement in survival is the gold We reviewed the regulatory history of the accelerated approval process and the US Food and Drug Administration (FDA) experience with accelerated approval of oncology products from its initiation in December 11, 1992, to July 1, 2010. The accelerated approval regulations allowed accelerated approval of products to treat serious or life-threatening diseases based on surrogate endpoints that are reasonably likely to predict clinical benefit. Failure to complete postapproval trials to confirm clinical benefit with due diligence could result in removal of the accelerated approval indication from the market. From December 11, 1992, to July 1, 2010, the FDA granted accelerated approval to 35 oncology products for 47 new indications. Clinical benefit was confirmed in postapproval trials for 26 of the 47 new indications, resulting in conversion to regular approval. The median time between accelerated approval and regular approval of oncology products was 3.9 years (range = 0.8-12.6 years) and the mean time was 4.7 years, representing a substantial time savings in terms of earlier availability of drugs to cancer patients. Three new indications did not show clinical benefit when confirmatory postapproval trials were completed and were subsequently removed from the market or had restricted distribution plans implemented. Confirmatory trials were not completed for 14 new indications. The five longest intervals from receipt of accelerated approval to July 1, 2010, without completion of trials to confirm clinical benefit were 10.5, 6.4, 5.5, 5.5, and 4.7 years. The five longest intervals between accelerated approval and successful conversion to regular approval were 12.6, 9.7, 8.1, 7.5, and 7.4 years. Trials to confirm clinical benefit should be part of the drug development plan and should be in progress at the time of an application seeking accelerated approval to prevent an ineffective drug from remaining on the market for an unacceptable time.
J Natl Cancer Inst 2011;103:636-644 standard, a better quality of life is an acceptable basis for regular approval of a drug. Drug approvals that are based on a better quality of life have generally involved drugs that prevent or ameliorate cancer-related symptoms. Such drugs include those that prevent or relieve pain (eg, mitoxantrone in hormone-refractory prostate cancer), morbidity from bone lesions (eg, bisphosphonates in multiple myeloma and solid tumors), cutaneous manifestations and disfigurement due to AIDS-related Kaposi sarcoma (eg, alitretinoin gel, paclitaxel, and liposomal doxorubicin), and cutaneous manifestations of cutaneous T-cell lymphoma (eg, bexarotene capsules, bexarotene gel, and methoxalen solution for use in a photophoresis system), palliate obstructing symptomatic esophageal cancer or endobronchial non-small cell lung cancer (eg, porfimer sodium for photodynamic therapy), and prevent or ameliorate drug toxicity (eg, amifostine for cisplatin-induced renal toxicity and dexrazoxane for anthracycline-induced cardiomyopathy). The use of quality-of-life instruments to assess quality of life (except for the assessment of pain) has not been the primary basis for approval of any oncology drug.
Treatment of cancer patients is directed at prolonging their life (improved survival) and/or giving them a better life. All other endpoints used in cancer clinical trials must be surrogates for one or both of these. Surrogate endpoints to predict improved survival or a better quality of life or may either be established to do so or be reasonably likely to do so. Established surrogates are the basis for regular approval. Reasonably likely surrogates are the basis for accelerated approval. Disease-free survival is an established surrogate for overall survival in some adjuvant indications where there is sufficient experience to validate it, such as colon cancer and breast cancer. The durable complete response rate has been used as an established surrogate for survival or a better quality of life in testicular cancer and acute leukemia.
Progression-free survival and time to progression are frequent primary endpoints in clinical trials in advanced cancer and are the most difficult endpoints for the Food and Drug Administration (FDA) to interpret when considering a drug for either regular or accelerated approval. Progression-free survival and time to progression are potential surrogates for improved survival or a better quality of life. For some indications, progression-free survival or time to progression is accepted by the FDA as an established surrogate and is the basis for regular approval of a drug. For example, the FDA used progression-free survival as an established surrogate to grant regular approval for gemcitabine for the treatment of advanced ovarian cancer after failure of platinum-based chemotherapy; the FDA used time to progression as an established surrogate to grant regular approval for lapatinib for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. For other indications (Table 1) , these endpoints have been accepted by the FDA as reasonably likely surrogates and have been the basis for accelerated approval of a drug. The criteria used by the FDA to determine whether progression-free survival or time to progression support regular approval or accelerated approval for a particular drug indication include whether there is an available therapy for the indication that improves survival. If an available therapy improves survival, the FDA is unlikely to grant regular approval based on progression-free survival or time to progression. In this situation, accelerated approval may be granted if the magnitude of the improvement in progression-free survival or time to progression is sufficient to be reasonably likely to predict a survival benefit superior to that with the available therapy. If there is no available therapy that improves survival, an improvement in progressionfree survival or time to progression of sufficient magnitude to assure a better quality of life and that possibly predicts improved survival may be the basis of regular approval. For both regular approval and accelerated approval, the toxicity to benefit ratio is an important consideration. A minimal amount of missing data and equal assessment on both treatment arms are essential to assure that progression-free survival or time to progression is reliably assessed. In addition, confirmation of investigator assessment of progression-free survival or time to progression by independent blinded radiology review is required by the FDA to avoid the possibility of investigator bias.
An example of the use of an improvement in progression-free survival as the basis for regular approval for a condition for which there is no effective therapy is the approval of sorafenib for advanced renal cell cancer. At the time of this approval, there were no effective treatments for advanced renal cell cancer. An improvement in progression-free survival with sorafenib was considered by the FDA to be a clinically significant advance compared with available therapy and thus regular approval was granted.
The progression-free survival endpoint is preferred by the FDA over time to progression because time to progression involves use of informative censoring; nevertheless, the FDA has used time to progression in some cases as a surrogate for clinical benefit. For example, the FDA used time to progression as the primary endpoint in randomized trials for accelerated approval of bicalutamide, in combination with luteinizing hormone-releasing hormone, for the treatment of stage D prostate cancer and for accelerated approval of oxaliplatin, in combination with 5-fluorouracil and lecovorin, for second-line therapy of metastatic colorectal cancer.
Other surrogate endpoints that have been used by the FDA as a basis for accelerated approval are partial response rate and response duration, major or complete cytogenetic response rate, and major molecular response rate. A good partial response rate of sufficient duration is often a reasonably likely surrogate for clinical benefit in refractory solid tumor indications or where there is no effective therapy and is the most frequent basis for accelerated approval. More recently, the major or complete cytogenetic response rate and the major molecular response rate have become reasonably likely surrogates for clinical benefit in chronic myelogenous leukemia.
The purpose of the accelerated approval regulation is to make drugs more rapidly available to cancer patients. The FDA has taken two policy initiatives to optimize the accelerated approval process and maximize the benefits of earlier availability of drugs to cancer patients. First, the accelerated approval regulations require that drugs that are granted accelerated approval be better than "available therapy." This requirement greatly limits the number of drugs that are granted accelerated approval, especially for refractory indications, because once a drug is granted accelerated approval for an indication, that drug would block future accelerated approvals for that indication because it would be the "available therapy." The FDA policy initiative that removes this roadblock specifies that a drug that is granted accelerated approval cannot be considered "available therapy" because clinical benefit has not been confirmed. Thus, cancer patients need not be nonresponsive to drugs granted accelerated approval to be considered nonresponsive to "available therapy." Second, postapproval trials to confirm clinical benefit for accelerated approvals need not be conducted in the same population as the trial that was considered for the accelerated approval and may be conducted in patients with a less advanced stage of the same cancer type. Otherwise, it may be difficult to accrue patients to a randomized confirmatory trial after the drug has already been shown to be reasonably likely to be better than available therapy.
The FDA considers "better than available therapy" to mean better efficacy. Although a drug with equal efficacy and less toxicity could possibly qualify as better than available therapy, the difference in toxicity must be substantial. Such a situation has not yet arisen.
The FDA experience with accelerated approval of oncology drugs from December 11, 1992, through January 1, 2004, was published in 2004 (7) . At that time, the FDA had granted accelerated approval of 22 new indications for 18 oncology products. Six of the 22 new indications had been converted to regular approval at that time. This article reports the FDA experience with accelerated approval of oncology drugs from December 11, 1992, to July 1, 2010.
Accelerated Approvals of Oncology Products
We searched FDA databases to identify products that had received accelerated approval from December 11, 1992, to July 1, 2010. We collected the following information: the basis for the accelerated approval, the status regarding conversion to regular approval, the basis for conversion to regular approval, whether the confirmatory trial(s) for conversion to regular approval resulted in a new indication, and Response rate * CML = chronic myelogenous leukemia; EGFR = epidermal growth factor receptor; FAP = familial adenomatous polyposis; FU/LV = 5-fluorouracil and leucovorin; GIST = gastrointestinal stromal tumor; HR = hormone receptor; ITP = idiopathic thrombocytopenic purpura; LHRH = luteinizing hormone-releasing hormone; NSCLC = non-small cell lung cancer; Ph = Philadelphia chromosome. † Accelerated approval instead of regular approval because of uncertainty about the ultimate outcome. ‡ Jewett-Whitmore staging system. the dates of accelerated approval and conversion to regular approval. Most of this information is publicly available in the approval letters and the drug labels, which can be found at the "Drugs@FDA" link at http://www.fda.gov. From December 11, 1992, to July 1, 2010, the FDA granted accelerated approval of 47 new indications for 35 anticancer drugs. Of the 47 accelerated approvals, 19 were based on randomized comparative trials (Table 1) and 28 were based on single-arm trials (Table 2 ). The surrogate endpoints for accelerated approval were objective response rate and duration (n = 36 indications), time to event (n = 9 indications), and improved safety (n = 2 indications).
For the 19 accelerated approvals based on randomized trials, the endpoints for accelerated approval were response rate and response duration (n = 9), time to event (ie, progression-free survival, time to progression, or disease-free survival; n = 9), and safety (ie, reduction in cardiomyopathy; n = 1). For the 28 accelerated Response rate * ALL = acute lymphocytic leukemia; AML = acute myelogenous leukemia; AP = accelerated phase; BC = blast crisis; CLL=chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; CRC = colorectal cancer; CTCL = cutaneous T-cell lymphoma; EGFR = epidermal growth factor receptor; GIST = gastrointestinal stromal tumor; NSCLC = non-small cell lung cancer; Ph = Philadelphia chromosome.
approvals based on single-arm trials, the accelerated approval endpoints were response rate and response duration (n = 27) and safety (ie, creatinine clearance; n = 1).
Accelerated Approval Instead of Regular Approval Because of Uncertainty of Ultimate Outcome
Six new indications (indicated by an asterisk in Tables 1 and 2) received accelerated approval based on endpoints that are considered established surrogates for clinical benefit in the approved indication. Accelerated approval was granted instead of regular approval because, although clinical benefit was demonstrated, the ultimate outcome was uncertain. Approval of dexrazoxane was based on a decrease in the incidence of cardiotoxicity and that of amifostine was based on a decrease in the incidence of cisplatinassociated renal toxicity, both of which are considered clinical benefit. However, because drugs that ameliorate the toxicity of an anticancer drug may also interfere with or abrogate the anticancer drug's efficacy, it was uncertain whether these drugs inhibited tumor growth. For anastrozole and letrozole, disease-free survival is considered an established surrogate for clinical benefit in the adjuvant treatment of breast cancer. However, the ultimate outcomes of survival and long-term toxicity were sufficiently uncertain that longer follow-up was needed. Imatinib prolonged the time to accelerated phase or blast crisis, which is considered an established surrogate for clinical benefit in chronic myelogenous leukemia in chronic phase. However, chronic myelogenous leukemia is a chronic disease with a relatively long survival and the ultimate outcome-survival duration-was uncertain.
Accelerated Approvals Converted to Regular Approval
Postapproval clinical trials performed with due diligence are required by the FDA to confirm clinical benefit and allow conversion of an accelerated approval to regular approval. Of the 47 new indications that received accelerated approval, 26 had clinical benefit confirmed in postapproval clinical trials and were converted to regular approval (Table 3) . Of the 26 indications initially granted accelerated approval and subsequently converted to regular approval, two were studied in single-arm postapproval trials and 24 were studied in randomized postapproval trials. The two accelerated approvals converted to regular approval based on response rate in single-arm trials were imatinib for pediatric Philadelphia chromosome-positive chronic myelogenous leukemia resistant to alpha interferon or recurrent after stem cell transplant and liposomal doxorubicin for second-line treatment of Kaposi sarcoma. The randomized trials to confirm the clinical benefit of dexrazoxane and liposomal doxorubicin were terminated because of poor patient accrual. The FDA used information from published trials to confirm the clinical benefit of dexrazoxane and liposomal doxorubicin and as the basis for their conversion to regular approval. Endpoints for confirmatory trials that were used by the FDA as the basis for converting an accelerated approval to regular approval were survival (n = 10 indications), progression-free survival or time to progression (n = 7 indications), response rate (n = 5 indications), disease-free survival (n = 3 indications), and cardiac safety (n = 1 indication) ( Table 3 ).
The required postapproval clinical trials to confirm clinical benefit may be conducted in patients with a less advanced stage of the cancer type than the population used as the basis for accelerated approval. Of the 26 accelerated approvals that were converted to regular approval, nine were based on trials conducted in patients with a less advanced stage of the cancer and resulted in approval of a new indication (Table 3 ). The ideal approach for accelerated approval of a new indication is a randomized trial that supports accelerated approval based on a reasonably likely surrogate endpoint and additional follow-up of the same trial that confirms clinical benefit. This approach assures assessment of clinical benefit in a timely manner. Such an approach has been the paradigm for approval of antiretroviral drugs for AIDS, for which accelerated approval is based on viral load at 24 weeks and conversion to regular approval is granted based on continuation of the trial and measurement of viral load at 48 weeks (8) .
The median time between accelerated approval and regular approval of oncology drugs for the 26 accelerated approval indications converted to regular approval was 3.9 years (range = 0.8-12.6 years), and the average time was 4.7 years, which represent a substantial time savings in terms of earlier availability of drugs to patients.
Accelerated Approvals Not Converted to Regular Approval
Of the 47 indications that received accelerated approval, 21 have not been converted to regular approval because clinical benefit has not been confirmed (Table 4) . Three of the drugs that received accelerated approval (amifostine, gemtuzumab ozogamicin, and gefitinib) failed to show clinical benefit (as well as any indication of a detrimental effect) in completed confirmatory trials. The accelerated approval indication for amifostine was voluntarily withdrawn by the applicant after completed clinical trials failed to confirm clinical benefit. Amifostine remains on the market for other indications. Gemtuzumab ozogamicin was withdrawn from the market after completed clinical trials did not confirm clinical benefit. Gefitinib was limited to restricted patient distribution by the FDA after completed clinical trials failed to confirm clinical benefit. Only patients taking gefitinib and benefiting from it before September 15, 2005, could receive the drug. The remaining 18 accelerated approval indications did not have confirmation of clinical benefit: 14 have not completed confirmatory trials and four have completed confirmatory trials and are under FDA review. The five longest intervals from receipt of accelerated approval to July 1, 2010 (the cutoff date for this review), without completion of trials to confirm clinical benefit are 10.5, 6.4, 5.5, 5.5, and 4.7 years (Table 4) .
Of the 21 accelerated approvals that have failed to show clinical benefit in confirmatory trials, eight were based on randomized trial design and 13 were based on a single-arm trial design. The endpoint used to establish clinical benefit and conversion to regular approval was response rate for 15 accelerated approvals, progressionfree survival for three, disease-free survival for one, incidence rate of colorectal polyps for one, and creatinine clearance for one.
Accelerated approvals that are based on response rate in single-arm trials may be less likely to show clinical benefit in confirmatory Survival, progression-free survival postapproval trials either because the trials fail to show clinical benefit or because the trials are not completed. As the following analysis shows, the answer is not clear. Of the 27 accelerated approvals based on response rate in single-arm trials, 15 (56%) showed clinical benefit in confirmatory postapproval trials and were converted to regular approval and 12 (44%) have not been converted. Three of the 12 accelerated approvals not converted to regular approval (amifostine, gemtuzumab ozogamicin, and gefitinib) have completed postapproval trials that did not confirm clinical benefit. The other nine accelerated approvals not converted to regular approval have not completed postapproval trials.
Among the 15 accelerated approvals that were converted to regular approval, the median time from accelerated approval to regular approval was 3.4 years (range = 1.0-12.6 years) and the average time was 4.6 years. The five longest intervals between accelerated approval and successful conversion to regular approval were 12.6, 9.7, 8.1, 7.5, and 7.4 years. Among the 12 accelerated approvals that have not been converted to regular approval, the four longest intervals from accelerated approval to July 1, 2010, are 6.4, 5.5, 5.5, and 4.7 years. It is notable that all three of the accelerated approvals for which postapproval trials were completed and failed to confirm clinical benefit (ie, amifostine, gemtuzumab ozogamicin, and gefitinib) used the single-arm trial design with response rate as the endpoint. Note that the FDA considered the gefitinib trial a single-arm trial even though two gefitinib doses were compared. The gefitinib trial was small, and the lower gefitinib dose had a better response rate. By comparison, of the 20 accelerated approvals that were not based on response rate in single-arm trials, 11 (55%) had clinical benefit confirmed in postapproval trials and were converted to regular approval and nine (45%) have not been converted to regular approval. Among the 11 accelerated approvals that were converted to regular approval, the median time from accelerated approval to regular approval was 4.9 years (range = 0.8-8.1 years) and the average time was 4.7 years. The four longest intervals between accelerated approval and regular approval are 8.1, 7.5, 7.4, and 5.5 years. Among the nine accelerated approvals that have not been converted to regular approval, the four longest intervals from accelerated approval to the July 1, 2010 cutoff date are 10.5, 4.1, 3.8, and 2.3 years.
Thus, there was no clear difference regarding the success or timing of subsequent conversion of accelerated approval to regular approval between single-arm trials with response rate as the primary endpoint and other trials. A possible explanation for the lack of a difference in successful conversion to accelerated approval between single-arm trials with response rate as the endpoint and other trials may be that the single-arm trials with response rate as the endpoint were conducted almost entirely in patients with cancer not responsive to available drugs. Of the 28 accelerated approvals that were based on single-arm trials with response rate as the primary endpoint, 25 were in patients who were not responsive to available drugs. Apparently, a good response rate and good response duration in patients with cancer not responsive to available drugs is a reasonably good predictor of success in confirmatory trials. However, for reasons indicated below, the FDA much prefers accelerated approvals that are based on data from randomized trials.
Discussion
From December 11, 1992, to July 1, 2010, the FDA granted accelerated approval of 47 new indications for 35 drugs. Postapproval trials have confirmed clinical benefit for 26 of the 47 new indications, and those have been converted to regular approval. The median time between accelerated approval and regular approval of oncology products was 3.9 years (range = 0.8-12.6 years) and the mean time was 4.7 years, which represents substantial time savings in terms of earlier availability of drugs to patients. Of the 21 accelerated approval indications that have not been converted to regular approval, three did not show clinical benefit in completed confirmatory clinical trials and have either been withdrawn from the market or restricted with regard to their patient distribution. The five longest intervals from receipt of accelerated approval to the July 1, 2010, cutoff date without completion of trials to confirm clinical benefit are 10.5, 6.4, 5.5, 5.5, and 4.7 years.
The accelerated approval process has been successful in making promising new drugs available to cancer patients sooner than they would have been if they had undergone regular approval. The two FDA concerns before implementation of the accelerated approval process were that ineffective drugs would be approved and the possible lack of due diligence in conducting postapproval trials to confirm clinical benefit. Three of 47 accelerated approvals subsequently failed to show clinical benefit in completed confirmatory postapproval trials. However, the extent to which ineffective drugs have been approved is uncertain because of the 47 accelerated approvals, 14 have not completed confirmatory trials and four have completed clinical trials that are currently under FDA review.
The process of removal of ineffective drug indications did not work well for amifostine or gemtuzumab ozogomycin, which required 10.0 and 10.1 years, respectively, after accelerated approval for the indication to be withdrawn from the market. The accelerated approval process worked reasonably well for gefitinib, which had its distribution restricted to patients who were already taking and benefiting from gefitinib starting 2.4 years after accelerated approval.
The due diligence in conducting postapproval trials to confirm clinical benefit has been suboptimal. Among the 14 accelerated approvals that do not have completed trials showing clinical benefit, the five longest intervals since accelerated approval up to the July 1, 2010, cutoff date are 10.5, 6.4, 5.5, 5.5, and 4.7 years. Of the 26 accelerated approvals with confirmation of clinical benefit in clinical trials, 11 had intervals of more than 5 years between accelerated approval and successful conversion to regular approval (range = 5.5-12.6 years) and the five longest intervals between accelerated approval and successful conversion to regular approval were 12.6, 9.7, 8.1, 7.5, and 7.4 years. Because of the possibility that confirmatory trials will not confirm clinical benefit, indications that have received accelerated approval should not be on the market for unacceptably prolonged intervals in the absence of completed trials to confirm clinical benefit. As indicated above, both the accelerated approval indications for amifostine and gemtuzumab ozogamicin were on the market for 10 years before confirmatory trials were completed and prompted withdrawal of the accelerated approval indication from the market.
Granting accelerated approval based on surrogate endpoints that are reasonably likely to predict clinical benefit entails some risk that cancer patients will be exposed to the adverse effects of an ineffective drug. Part of the risk involves the length of time that may be required to complete confirmatory trials so that the indication can either be converted to regular approval or removed from the market. For example, knowing that a confirmatory trial(s) will be completed in 1 year entails substantially less risk of exposing large numbers of cancer patients to the adverse effects of an ineffective drug compared with knowing that it will take 7 years for trial completion or having no good estimate of when or whether confirmatory trial(s) will be completed. This issue must be considered by the FDA in deciding whether each accelerated approval will be granted.
The FDA is limited to issues of safety and efficacy when making drug approval decisions. However, the financial costs to consumers and taxpayers of drugs that remain on the market for a long time that ultimately fail to confirm clinical benefit in postapproval trials is an important consideration. The FDA has no authorization to consider cost in any of its approval decisions. Thus, the costbenefit aspect of the accelerated approval program is not discussed here.
The most common approach used by pharmaceutical companies to gain accelerated approval has been single-arm trials that have an endpoint of response rate in patients who are refractory to all available therapies. There are several problems with this approach. First, it is essential to document refractoriness for each patient for all available therapies. This means documenting that there was an adequate trial of every available therapy and that patients had progressed on at least the most recent therapy, which is sometimes difficult to do. Second, because so many therapies are available for some cancers, it can be impractical to accrue a sufficient number of patients who have had an adequate trial of all available therapies using appropriate doses and schedules and for reasonable treatment durations. In addition, a determination about what constitutes available therapies is made at the time that the FDA makes an approval decision on the marketing application. The status of available therapy for the indication may have changed substantially during the interval between the start of clinical drug development and the time of the FDA marketing approval decision. Third, the fact that a patient has survived long enough to have had all available therapies may indicate that the patient has a favorable cancer that is not representative of that cancer type. Fourth, only response rate can be assessed in single-arm trials. Time-to-event endpoints require randomized trials. Fifth, small single-arm trials do not provide an adequate safety database.
By contrast, randomized trials are the optimal approach to gaining accelerated approval for a new drug indication for the following reasons. First, accelerated approval can be granted based on a reasonably likely surrogate endpoint in a randomized clinical trial, and continuation of the trial can confirm clinical benefit and allow conversion of the accelerated approval to regular approval. Second, randomized trials allow time-to-event endpoints and combination regimens with an add-on design to be assessed. Finally, because the trial is likely to be relatively advanced at the time of accelerated approval, completion of the trial with due diligence is assured.
Too frequently, the issue of accelerated approval first arises at the time of application submission to the FDA when sufficient time and attention may not have been paid to how accelerated approval would be part of the development plan. There may be no confirmatory trial in progress, no protocol for a confirmatory trial, and no assurance that a trial protocol can be developed that will accrue patients. Sometimes a phase I trial must first be conducted using the new investigational drug in combination with another drug before the confirmatory trial is conducted with the new combination. In this situation, the FDA must consider the risk of approving an ineffective drug that may remain on the market for an extended or an indefinite time because confirmatory trials will not be completed for a long time or may never be completed.
One solution to the lack of due diligence issue is for the FDA to require that a confirmatory trial be in progress before granting accelerated approval. Such a requirement would ensure that accelerated approval is part of the development plan of a drug for a new indication and not an afterthought.
Lack of due diligence in conducting confirmatory trials is a serious concern that has threatened the continuation of the accelerated approval process. Before the FDA grants accelerated approval of a new indication for a drug, the pharmaceutical company is required to commit to a confirmatory trial protocol submission date (if one was not already submitted), a confirmatory trial completion date, and a study report submission date. Accelerated approval is granted only if the FDA agrees that these timelines are reasonable. Until recently, the only option available to the FDA for addressing a lack of due diligence by the pharmaceutical company in keeping these commitments was to revoke the accelerated approval. However, removing a drug from the market solely because of lack of due diligence when the only available evidence of efficacy is that the drug is reasonably likely to have better clinical benefit than available therapy may be an appropriate sanction against the pharmaceutical company but may not be in the best interest of cancer patients. Thus, this is not an attractive option and has never been done for an anticancer drug. The US Congress has recently addressed this problem by passing the Food, Drug and Cosmetic Act of 2007 (9), which gave the FDA authority to assess monetary penalties up to $10 million on pharmaceutical companies for lack of due diligence in completing confirmatory trials for drugs granted accelerated approval (10). The FDA believes that this will be an effective new tool for dealing with lack of due diligence.
